Definium Therapeutics (DFTX) Other Non-Current Liabilities (2021 - 2026)
Definium Therapeutics (DFTX) posted quarterly Other Non-Current Liabilities of $559000.0 for Q1 2026, down 96.87% year-over-year from $17.8 million in Q1 2025, and up 12.7% quarter-over-quarter from $496000.0 in Q4 2025.
Powered by 
Analysis
Definium Therapeutics (DFTX) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has reported Other Non-Current Liabilities for 6 consecutive years, with $559000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 96.87% year-over-year to $559000.0; the TTM figure through Mar 2026 stood at $559000.0 (down 96.87% YoY), while the FY2025 annual figure was $496000.0, down 98.03% from the prior year.
- Other Non-Current Liabilities grew to $559000.0 in Q1 2026 per DFTX's latest filing, from $496000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $25.2 million in Q4 2024 and bottomed at $15000.0 in Q1 2024.
- Historically, Other Non-Current Liabilities has averaged $4.5 million across 5 years, with a median of $966000.0 in 2024.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities slumped 98.62% — and 2025, when it jumped 118866.67%.
- Definium Therapeutics' Other Non-Current Liabilities stood at $1.2 million in 2022, then sank by 97.3% to $32000.0 in 2023, then soared by 78518.75% to $25.2 million in 2024, then tumbled by 98.03% to $496000.0 in 2025, then climbed by 12.7% to $559000.0 in 2026.
- Business Quant data shows DFTX's Other Non-Current Liabilities at $559000.0 in Q1 2026, $496000.0 in Q4 2025, and $519000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Definium Therapeutics | 4.23 Bn | 4.23 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 549,000.00 |
| Mar 31, 2026 | 559,000.00 |
| Dec 31, 2025 | 496,000.00 |
| Sep 30, 2025 | 519,000.00 |
| Jun 30, 2025 | 543,000.00 |
| Mar 31, 2025 | 17.85 Mn |
| Dec 31, 2024 | 25.16 Mn |
| Sep 30, 2024 | 22.32 Mn |
| Jun 30, 2024 | 30.68 Mn |
| Mar 31, 2024 | 15,000.00 |
| Dec 31, 2023 | 32,000.00 |
| Sep 30, 2023 | 349,000.00 |
| Jun 30, 2023 | 992,000.00 |
| Mar 31, 2023 | 1.09 Mn |
| Dec 31, 2022 | 1.18 Mn |
| Sep 30, 2022 | 1.28 Mn |
| Jun 30, 2022 | 1.90 Mn |
| Mar 31, 2022 | 490,000.00 |
| Dec 31, 2021 | 1.93 Mn |